{"filing":{"accession_number":"0001731122-26-001211","cik":"0001314052","ticker":"AVXL","company_name":"ANAVEX LIFE SCIENCES CORP.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"e7928_8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001211/e7928_8-k.htm"},"events":[{"id":32430,"run_id":29794,"accession_number":"0001731122-26-001211","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure reports that the FDA has granted Anavex's request for a meeting to discuss inclusion of pediatric patients in its Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome. This is a material regulatory milestone in the company's clinical development pipeline for a lead candidate, affecting the scope and timeline of a pivotal trial. While not a specific named event type, this is clearly an operational/clinical development matter material to investors assessing the company's drug development progress.","company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35598,"accession_number":"0001731122-26-001211","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports that the FDA has granted Anavex's request for a meeting to discuss inclusion of pediatric patients in its Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome. This is a material regulatory milestone in the company's clinical development pipeline for a lead candidate, affecting the scope and timeline of a pivotal trial. While not a specific named event type, this is clearly an operational/clinical development matter material to investors assessing the company's drug development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T21:20:14.132091+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35598,"accession_number":"0001731122-26-001211","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports that the FDA has granted Anavex's request for a meeting to discuss inclusion of pediatric patients in its Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome. This is a material regulatory milestone in the company's clinical development pipeline for a lead candidate, affecting the scope and timeline of a pivotal trial. While not a specific named event type, this is clearly an operational/clinical development matter material to investors assessing the company's drug development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T21:20:14.132091+00:00","company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","filing_date":"2026-09-09"}]}